Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 1% to $8.06. The company on Mar. 24 announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) opened today at $8.05 and is currently trading at $8.31. The stock showed a positive weekly performance of 6.05%.
Progenics Pharmaceuticals, Inc. (PGNX) reported a loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents, but wider than the year-ago loss of 1 cent per share. Fourth quarter revenues were $2.968 million, down 66.6% from the year-ago quarter. Revenues, however, surpassed the Zacks Consensus Estimate of $2 million. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) opened at $4.02, in current trading session and currently is at $4.23, by gaining 3.42%. The 52 week range of $ 3.45 – 7.45. Company’s market capitalization is $ 294.30 Million.
Celladon Corp (NASDAQ:CLDN) has sold its entire stake in Oval, a leading provider of insurance broking and financial services in the UK, to Friary Intermediate a wholly-owned subsidiary of Arthur J. Gallagher & Co as part of the acquisition by Gallagher of the entire Oval group. The transaction values Oval at £210m. Celladon Corp (NASDAQ:CLDN) stock is currently trading at $ 11.57. The EPS of the stock is -1.21. Company’s market capitalization is $212.94 Million.
Venaxis, Inc. (Nasdaq:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis™ has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA). Venaxis Inc (NASDAQ:APPY) stock opened the session at $2.66, and now is at 2.79$. The 52 week range of the APPY stock remained $1.15 – 3.88 and the day range was $ 2.65 – 2.83.